Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Bid for Orchid Cellmark for Ninth Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its cash tender offer for Orchid Cellmark for the ninth time as it continues to address questions from regulators about the proposed $85.4 million deal.

Today, LabCorp said it has extended its cash tender offer to 5 p.m. Nov. 30, after its prior extension to Nov.14 expired. In a statement, the company said that continues to cooperate with the Federal Trade Commission's request for additional information.

Also, it said that in order to allow more time to complete the deal, LabCorp, its subsidiary, OCM Acquisition, and Orchid have amended their merger agreement to extend the Extended Outside Date of the offer by an additional 30 calendar days to Dec. 14.

The depositary for the tender offer has told LabCorp that as of 5 p.m. Nov. 14, shareholders of Orchid had validly tendered and not withdrawn 26,064,267 shares of the company's stock, or about 86.8 percent of Orchid's outstanding shares. On a fully diluted basis, the figure represents about 79.7 percent of Orchid shares.

There were no shares tendered through uncovered notices of guaranteed delivery.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.